Federal contract award
75F40121C00162
THERE IS INCREASING RECOGNITION OF THE IMPORTANT ROLE OF PATIENT-FOCUSED DRUG DEVELOPMENT (PFDD) IN ONCOLOGY. REFLECTING THIS, THE FDA?S ONCOLOGY CENTER OF EXCELLENCE'S (OCE) PFDD PROGRAM IDENTIFIES RESEARCH INTO MEASUREMENT OF PATIENT EXPERI
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST NO FEE |
| Obligations | $347.8K |
| Current contract value | $347.8K |
| Potential contract value / ceiling | $347.8K |
| Start date | Sep 27, 2021 |
| Current end date | Dec 30, 2024 |
| Potential end date | Dec 30, 2024 |
| Latest award activity | Jun 10, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jun 10, 2025 | P00005 | $-2.6K | THE PURPOSE OF THIS MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE END DATE TO DECEMBER 30, 2024. |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.